Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik; Elena Garralda; Işıl Altıntaş; Friederike Gieseke; Ravit Geva; Eytan Ben‐Ami; Corinne Maurice‐Dror; Emiliano Calvo; Patricia LoRusso; Guzmán Alonso; María E. Rodriguez-Ruiz; Kristina B. Schoedel; Jordan M. Blum; Bianca Sänger; Theodora W. Salcedo; Saskia M. Burm; Eliana Stanganello; Dennis Verzijl; Fulvia Vascotto; Angelica Sette; Juliane Quinkhardt; Theo S. Plantinga; Aras Toker; Edward N. van den Brink; Mark Fereshteh; Mustafa Diken; David Satijn; Sebastian Kreiter; Esther C.W. Breij; Gaurav Bajaj; Eleni Lagkadinou; Kate Sasser; Özlem Türeci; Ulf Forssmann; Tahamtan Ahmadi; Uğur Şahin; Maria Jure‐Kunkel; Ignacio Melero

doi:10.1158/2159-8290.30834200

Abstract

Pharmacokinetics and pharmacodynamics of GEN1046 in patients with advanced solid tumors. A, Mean plasma concentration of GEN1046 during the first two dosing cycles with administration Q3W. B and C, Maximal fold change from baseline in pharmacodynamic markers measured in peripheral blood during cycle 1 in patients receiving low (≤200 mg) and high (≥400 mg) doses of GEN1046. P values from the Wilcoxon–Mann–Whitney test. LLOQ, lower limit of quantification.

Related Publications

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer , Charles G. Drake , Ira Wollner +17 more

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...

2010 Journal of Clinical Oncology 2881 citations

Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China

Wen-rui Zhang , Kun Wang , Lu Yin +17 more

Objective: We explored whether medical health workers had more psychosocial problems than nonmedical health workers during the COVID-19 out...

2020 Psychotherapy and Psychosomatics 1695 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell , Sandrine Faivre , Howard A. Burris +11 more

Purpose To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001). Methods We performed a dose-escalation study in advan...

2008 Journal of Clinical Oncology 474 citations

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

Jeffrey S. Weber , Steven O’Day , Walter J. Urba +5 more

Purpose The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Seconda...

2008 Journal of Clinical Oncology 458 citations

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Evan J. Lipson , William H. Sharfman , Charles G. Drake +10 more

Abstract Purpose: Results from the first-in-human phase I trial of the anti–programmed death-1 (PD-1) antibody BMS-936558 in patients with treatment-refractory solid tumors, inc...

2012 Clinical Cancer Research 529 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Alexander Muik, 
                                
                                    Elena Garralda, 
                                
                                    Işıl Altıntaş
                                
                                et al.
                            
                            (2025). 
                            Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30834200

Identifiers

DOI: 10.1158/2159-8290.30834200